Details:
Alladapt in their important goal of developing a single therapeutic ADP101, to address a wide range of mono- and multi-food allergies, and looking forward to fulfilling their Phase III and commercial requirements.
Lead Product(s): ADP101
Therapeutic Area: Immunology Product Name: ADP101
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Alladapt Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2022